{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:53:34Z","timestamp":1789066414720,"version":"build-2803163510"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The advent of antimicrobials was a miracle that saved millions of lives across the globe. With the discovery of penicillin, varieties of other antimicrobials came into play one after another. However, the injudicious use of antimicrobials for therapeutics and prophylactics and overuse in agriculture and animal husbandry industries resulted in its gloominess and rise of antimicrobial resistance. The microbes have slowly outsmarted the human race with diverse mechanisms to evade the antimicrobial effects of the drugs in use. The review aims to discuss the emergence of resistance in bacterial species with time and the various means by which bacterial cells had safeguarded themselves. In addition to that, we have also highlighted new approaches currently used to tackle antimicrobial resistance or practices that could be useful in identifying new treatment options.<\/jats:p>","DOI":"10.3389\/fphar.2022.838092","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:32:56Z","timestamp":1654263176000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Next-Generation Approaches Needed to Tackle Antimicrobial Resistance for the Development of Novel Therapies Against the Deadly Pathogens"],"prefix":"10.3389","volume":"13","author":[{"given":"Vasundhra","family":"Bhandari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"B1","first-page":"330","article-title":"A Meta-Analysis on Field Experiences with Vaccination against Ileitis Showing a Reduction on Antibiotics Use","author":"Adam","year":"2009"},{"key":"B2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/443754a","article-title":"The Road to Phage Therapy","volume":"443","author":"Adhya","year":"2006","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1021\/acsinfecdis.0c00026","article-title":"Innovation in Antimicrobial Resistance: The CARB-X Perspective","volume":"6","author":"Alm","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1056\/NEJMoa051926","article-title":"Human Botulism Immune Globulin for the Treatment of Infant Botulism","volume":"354","author":"Arnon","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B5","volume-title":"PubMed","author":"Author Anonymous","year":"2022"},{"key":"B6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.micpath.2019.03.003","article-title":"Host-Directed Therapies to Combat Tuberculosis and Associated Non-communicable Diseases","volume":"130","author":"Baindara","year":"2019","journal-title":"Microb. Pathog."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/archderm.1939.01490010004001","article-title":"Treatment-resistant Syphilis","volume":"40","author":"Beckh","year":"1939","journal-title":"Arch. Derm. Syphilol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3389\/fimmu.2020.01209","article-title":"Host Directed Therapy against Infection by Boosting Innate Immunity","volume":"11","author":"Bergman","year":"2020","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nbt.3043","article-title":"Exploiting CRISPR-Cas Nucleases to Produce Sequence-specific Antimicrobials","volume":"32","author":"Bikard","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41467-017-02123-w","article-title":"Protein-inspired Antibiotics Active against Vancomycin- and Daptomycin-Resistant Bacteria","volume":"9","author":"Blaskovich","year":"2018","journal-title":"Nat. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"12868","DOI":"10.1073\/pnas.1717157115","article-title":"Antimicrobial Resistance and the Role of Vaccines","volume":"115","author":"Bloom","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-virology-101416-041616","article-title":"The Discovery, Mechanisms, and Evolutionary Impact of Anti-CRISPRs","volume":"4","author":"Borges","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/joim.12777","article-title":"Vitamin D and Tuberculosis: Where Next?","volume":"284","author":"Brighenti","year":"2018","journal-title":"J. Intern Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijid.2019.10.005","article-title":"Impact of Vaccines on Antimicrobial Resistance","volume":"90","author":"Buchy","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0148857","DOI":"10.1371\/journal.pone.0148857","article-title":"Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation","volume":"11","author":"Caselli","year":"2016","journal-title":"PLOS ONE"},{"key":"B16","volume-title":"Antibiotic-resistant Germs: New Threats","author":"Cdc","year":"2021"},{"key":"B17","volume-title":"What Exactly Is Antibiotic Resistance?","author":"Cdc","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrmicro1818","article-title":"The Biology and Future Prospects of Antivirulence Therapies","volume":"6","author":"Cegelski","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/cc13176","article-title":"Targeting the Programmed Cell Death 1: Programmed Cell Death Ligand 1 Pathway Reverses T Cell Exhaustion in Patients with Sepsis","volume":"18","author":"Chang","year":"2014","journal-title":"Crit. Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/nbt.3011","article-title":"Sequence-specific Antimicrobials Using Efficiently Delivered RNA-Guided Nucleases","volume":"32","author":"Citorik","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1128\/MMBR.00016-10","article-title":"Origins and Evolution of Antibiotic Resistance","volume":"74","author":"Davies","year":"2010","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2334-14-166","article-title":"Interferon-Gamma as Adjunctive Immunotherapy for Invasive Fungal Infections: A Case Series","volume":"14","author":"Delsing","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd.2017.23","article-title":"Different Drugs for Bad Bugs: Antivirulence Strategies in the Age of Antibiotic Resistance","volume":"16","author":"Dickey","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B24","volume-title":"DNDi \\textbar Best Science for the Most Neglected","author":"DNDi","year":"2021"},{"key":"B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1368-7646(98)80214-8","article-title":"Mobile Elements in the Evolution and Spread of Multiple-Drug Resistance in Staphylococci","volume":"1","author":"Firth","year":"1998","journal-title":"Drug resist. updat."},{"key":"B26","volume-title":"Global Antibiotic Research and Development Partnership","author":"Gardp","year":"2022"},{"key":"B27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3201\/eid2305.161556","article-title":"The Discovery of Penicillin-New Insights after More Than 75 Years of Clinical Use","volume":"23","author":"Gaynes","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"B28","unstructured":"GDP Ranked by Country 20212021"},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.22376\/ijpbs.2016.7.4.p47-53","article-title":"Assets and Liabilities of Drug Repositioning","volume":"7","author":"Gill","year":"2016","journal-title":"Int. J. Pharm. Bio Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1021\/acsinfecdis.9b00357","article-title":"Liposomes for Antibiotic Encapsulation and Delivery","volume":"6","author":"Gonzalez Gomez","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/antibiotics9110827","article-title":"Phage Therapy: Towards a Successful Clinical Trial","volume":"9","author":"G\u00f3rski","year":"2020","journal-title":"Antibiotics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","article-title":"Estimating the Cost of Vaccine Development against Epidemic Infectious Diseases: a Cost Minimisation Study","volume":"6","author":"Gouglas","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40265-016-0577-0","article-title":"Obiltoxaximab: First Global Approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1517\/13543784.9.8.1723","article-title":"Cationic Antimicrobial Peptides: towards Clinical Applications","volume":"9","author":"Hancock","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1128\/AAC.43.6.1317","article-title":"Peptide Antibiotics","volume":"43","author":"Hancock","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S1473-3099(13)70001-X","article-title":"Immunosuppression in Sepsis: A Novel Understanding of the Disorder and a New Therapeutic Approach","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"582779","DOI":"10.3389\/fmicb.2020.582779","article-title":"Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields","volume":"11","author":"Huan","year":"2020","journal-title":"Front. Microbiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nm.4465","article-title":"The Role of Vaccines in Preventing Bacterial Antimicrobial Resistance","volume":"24","author":"Jansen","year":"2018","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0084-3873(10)79679-6","article-title":"Treatment with Monoclonal Antibodies against Clostridium difficile Toxins","volume":"2010","author":"Khardori","year":"2010","journal-title":"Yearb. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/13543776.2016.1176149","article-title":"Antimicrobial Peptides (AMPs) as Drug Candidates: a Patent Review (2003-2015)","volume":"26","author":"Kosikowska","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"B41","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/v5030806","article-title":"Understanding Bacteriophage Specificity in Natural Microbial Communities","volume":"5","author":"Koskella","year":"2013","journal-title":"Viruses"},{"key":"B42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4161\/bact.1.2.14590","article-title":"Pros and Cons of Phage Therapy","volume":"1","author":"Loc-Carrillo","year":"2011","journal-title":"Bacteriophage"},{"key":"B43","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: an International Expert Proposal for Interim Standard Definitions for Acquired Resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fcimb.2016.00194","article-title":"Antimicrobial Peptides: An Emerging Category of Therapeutic Agents","volume":"6","author":"Mahlapuu","year":"2016","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the Treatment of Inhalational Anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B46","volume-title":"Research \\& Development \\textbar Medicines for Malaria Venture","author":"Mmv","year":"2021"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41564-021-00920-0","article-title":"Probiotics Impact the Antibiotic Resistance Gene Reservoir along the Human GI Tract in a Person-specific and Antibiotic-dependent Manner","volume":"6","author":"Montassier","year":"2021","journal-title":"Nat. Microbiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tibtech.2011.05.001","article-title":"The Expanding Scope of Antimicrobial Peptide Structures and Their Modes of Action","volume":"29","author":"Nguyen","year":"2011","journal-title":"Trends Biotechnol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41577-018-0094-3","article-title":"Statins: A Viable Candidate for Host-Directed Therapy against Infectious Diseases","volume":"19","author":"Parihar","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrmicro.2017.120","article-title":"Anti-CRISPR: Discovery, Mechanism and Function","volume":"16","author":"Pawluk","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1086\/314535","article-title":"Perspective: A Five-Country Analysis of the Impact of Four Different Haemophilus Influenzae Type B Conjugates and Vaccination Strategies in Scandinavia","volume":"179","author":"Peltola","year":"1999","journal-title":"J. Infect. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imr.12567","article-title":"Gut Microbiota: Role in Pathogen Colonization, Immune Responses, and Inflammatory Disease","volume":"279","author":"Pickard","year":"2017","journal-title":"Immunol. Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The Complexity and Cost of Vaccine Manufacturing - an Overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3389\/fphar.2019.00513","article-title":"Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections","volume":"10","author":"Principi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1006990","DOI":"10.1371\/journal.ppat.1006990","article-title":"CRISPR-cas Antimicrobials: Challenges and Future Prospects","volume":"14","author":"Pursey","year":"2018","journal-title":"PLOS Pathog."},{"key":"B56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/cc13797","article-title":"Pharmacological Management of Tetanus: an Evidence-Based Review","volume":"18","author":"Rodrigo","year":"2014","journal-title":"Crit. Care"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fimmu.2020.01048","article-title":"Vaccines against Antimicrobial Resistance","volume":"11","author":"Rosini","year":"2020","journal-title":"Front. Immunol."},{"key":"B58","volume-title":"Drug Repurposing (DR): An Emerging Approach in Drug Discovery","author":"Rudrapal","year":"2020"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e00954","DOI":"10.1128\/AAC.00954-17","article-title":"Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails to Treat a Patient with a Disseminated Resistant Acinetobacter Baumannii Infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"104080","DOI":"10.1016\/j.jff.2020.104080","article-title":"Probiotics as an Alternative Antimicrobial Therapy: Current Reality and Future Directions","volume":"73","author":"Silva","year":"2020","journal-title":"J. Funct. Foods"},{"key":"B61","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrmicro1234","article-title":"Mechanisms of, and Barriers to, Horizontal Gene Transfer between Bacteria","volume":"3","author":"Thomas","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/antibiotics10111287","article-title":"Mobile Antimicrobial Resistance Genes in Probiotics","volume":"10","author":"T\u00f3th","year":"2021","journal-title":"Antibiotics"},{"key":"B63","first-page":"336","article-title":"Reduction of Antibiotics after Implementing PCV2 Vaccination on 460 Sow Dutch Pigfarm","author":"van Dommelen","year":"2011"},{"key":"B64","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2307\/375519610.1080\/00275514.1947.12017635","article-title":"What Is an Antibiotic or an Antibiotic Substance?","volume":"39","author":"Waksman","year":"1947","journal-title":"Mycologia"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1128\/9781555817886","volume-title":"Antibiotics: Actions, Origins, Resistance","author":"Walsh","year":"2003"},{"key":"B66","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2217\/17460913.3.5.547","article-title":"Acquired Vancomycin Resistance in Clinically Relevant Pathogens","volume":"3","author":"Werner","year":"2008","journal-title":"Future Microbiol."},{"key":"B67","volume-title":"Immunization Coverage","author":"Who","year":"2020"},{"key":"B68","doi-asserted-by":"publisher","first-page":"698S","DOI":"10.3945\/jn.109.113753","article-title":"Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Prevention and Management of Infections by Probiotics","volume":"140","author":"Wolvers","year":"2010","journal-title":"J. Nutr."},{"key":"B69","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/509555a","article-title":"Policy: An Intergovernmental Panel on Antimicrobial Resistance","volume":"509","author":"Woolhouse","year":"2014","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming Cancer Therapeutic Bottleneck by Drug Repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3389\/fmicb.2017.00908","article-title":"Assessing the Risk of Probiotic Dietary Supplements in the Context of Antibiotic Resistance","volume":"8","author":"Zheng","year":"2017","journal-title":"Front. Microbiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.838092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:33:05Z","timestamp":1654263185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.838092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":71,"alternative-id":["10.3389\/fphar.2022.838092"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.838092","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"article-number":"838092"}}